Although antibodies to HLA play a role in the pathogenesis of diseases processes such as rejection of transplanted organs, the precise mechanisms by which antibodies cause tissue injury are not completely understood. We hypothesized that antibodies to host tissues cause inflammation in part by activating endothelial exocytosis of granules that contain prothrombotic mediators such as von Willebrand Factor (VWF) and proinflammatory mediators such as P-selectin. To test this hypothesis, we treated human endothelial cells with murine monoclonal antibody W6/32 to HLA class I and then measured exocytosis by the release of VWF and the externalization of P-selectin. Antibody to HLA activates endothelial exocytosis in a dose-dependent manner over time. The biologically active complement split product, C5a, adds a slight but significant increase to antibody induction of exocytosis. Antibody to HLA alone or with C5a did not damage the cells. Cross-linking of HLA appears to play a role in the ability of antibody to activate exocytosis, because the W6/32 monovalent Fab fragment did not activate VWF release, but the bivalent F(ab) 2 was effective in triggering exocytosis. To explore the in vivo effects of antibody upon graft injury, we infused W6/32 F(ab)2 antibody to human HLA into severe combined immunodeficient/beige mice that had been transplanted with human skin grafts. Antibody to HLA activated exocytosis and inflammation in human skin grafts. Our data show that antibody to host antigens can activate human endothelial cell exocytosis and leukocyte trafficking. By triggering vascular inflammation, antibody activation of exocytosis may play a role in transplant rejection.
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nitric oxide ͉ rejection ͉ transplant ͉ vasculopathy ͉ Weibel-Palade body R ejection of transplants in immunologically naïve experimental animals is mediated primarily by T cells. In contrast, most human transplant recipients are not immunologically naïve. Many of these patients have had transfusions of blood products, pregnancy, or previous transplants that result in the production of antibody to HLA and the formation of memory B cells (1, 2) . Transplanted patients with antibodies to HLA have increased rejection episodes and respond poorly to conventional immunosuppression (2) (3) (4) (5) . Recent clinical studies suggest that antibodies play a key role in the majority of irreversible acute rejections (6) .
The vascular endothelium is a major target of antibody-mediated rejection (7) (8) (9) (10) . Low titers of antibodies are associated with endothelial cell swelling, platelet aggregation, and macrophage accumulation (4, 5) . Antibodies to HLA can bind to class I molecules on the surface of endothelial cells, stimulating proliferation and activating cell survival pathways (8) . However, the mechanisms by which antibody to HLA damages the endothelium are not well understood (11) .
Platelet aggregation and macrophage accumulation can be promoted by endothelial exocytosis, in which the Weibel-Palade body storage granules within endothelial cells fuse with the plasma membrane, releasing von Willebrand factor (VWF) and externalizing P-selectin (12, 13) . Once released, VWF can mediate platelet aggregation. Externalized P-selectin can trigger leukocyte rolling, the first stage in leukocyte trafficking.
We hypothesized that antibodies induce graft rejection in part by activating endothelial cell exocytosis. Endothelial exocytosis in turn would lead to thrombosis and inflammation in the graft. We therefore examined the effect of antibody to HLA upon human endothelial cells.
Results
Antibody to HLA Stimulates Weibel-Palade Body Exocytosis. To explore the effect of antibody to HLA upon endothelial exocytosis, we treated human aortic endothelial cells (HAEC) with the pan-HLA antibody W6/32 (which recognizes a monomorphic determinant on all HLA class I molecules) and measured the release of VWF. Antibody to HLA stimulates the release of VWF in a dose-dependent manner (Fig. 1A) . In contrast, the control antibody IgG does not. We repeated this experiment, using a different antibody to HLA, and found similar results: the monoclonal antibody G46-2.6 (an IgG1 that recognizes a monomorphic epitope of HLA Class I antigens) also activates endothelial exocytosis [supporting information (SI) Fig. 8 ]. Antibody to HLA rapidly stimulates endothelial cell exocytosis of VWF within 15 min, and the release of VWF continues 60 min after treatment (Fig. 1B) . We also found that antibody to HLA stimulates the translocation of Pselectin to the endothelial surface (Fig. 1C) . Because both VWF and P-selectin are stored in endothelial granules, taken together, these data suggest that antibody to HLA triggers exocytosis of endothelial granules.
As controls, we found that antibody does not damage endothelial cells. In particular, the antibody to HLA is not cytotoxic at the doses used, as assayed by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay (Fig. 1D) . Furthermore, the antibody to HLA does not cause apoptosis, as assayed by FACS (Fig. 1E) . We also examined the effect of adding thrombin and antibody together to endothelial cells. Thrombin, a strong activator of endothelial cell exocytosis, induces an additional release of VWF in cells treated with antibody to HLA (SI Fig. 9 ). These data show that antibody to HLA class I can activate endothelial exocytosis, but that the extent of stimulation produced by antibody alone is submaximal.
Does antibody also activate exocytosis of microvascular endothelial cells? We added antibody to HLA to human dermal micro-vascular endothelial cells (HMVEC) and found that the antibody again stimulated VWF release in a dose-and a time-dependent manner (Figs. 1 F and G) . These data suggest that antibody can activate exocytosis from aortic and microvascular endothelial cells. Because specific classes of antibody can activate complement, we were interested in the effects of complement alone or complement with antibody upon endothelial exocytosis. Endothelial cells express the C5a receptor, and C5a has been shown to cause the release of VWF (14, 15). Recombinant C5a alone induces VWF release in a dose-and time-dependent manner, and C5a is not toxic to cells (Fig. 2) .
We next modeled antibody activation of complement by adding both antibody and C5a to endothelial cells. Adding increasing concentrations of C5a and constant amounts of antibody further increases VWF release (Fig. 3A) . Similarly, adding increasing amounts of antibody with fixed levels of C5a also increase endothelial exocytosis (Fig. 3B) . Taken together, these data suggest that C5a induces limited endothelial exocytosis, but that the effects are additive with that of antibody. cells, we used an inhibitor of exocytosis. This inhibitor of exocytosis was designed to target NSF, a critical component of the exocytic machinery (16) (17) (18) . We developed a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits NSF. This fusion peptide, designated TAT-NSF222, inhibits NSF ATPase activity, decreases endothelial exocytosis, and blocks inflammation in mice (18) (19) (20) . We pretreated endothelial cells with TAT-NSF222, then added antibody to HLA and measured the release of VWF. Antibody to HLA activates VWF release, but the exocytosis inhibitor TAT-NSF222 decreases VWF release (Fig. 4A) . In contrast, the control polypeptide, TAT-NSF222scr (with intact TAT sequence but scrambled NSF domain) has no effect upon exocytosis. Furthermore, the TAT-NSF peptide has no effect upon surface HLA expression (SI Fig. 10 ). These data show that antibody induces release of VWF through an NSF-dependent pathway.
Calcium plays a critical role in exocytic pathways (17) . To examine whether calcium signaling is required for antibody triggered release of VWF, we incubated endothelial cells with media alone, calcium-free media, or 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetate (BAPTA; to disperse intracellular calcium storage pools). Although antibody to HLA can trigger VWF release from control cells, pretreatment with BAPTA greatly diminishes VWF release (Fig. 4B) . Furthermore, BAPTA has no effect upon surface HLA expression (SI Fig. 11 ). Taken together, these results suggest that antibody to HLA induces release of VWF by activating endothelial exocytosis.
Fragments of Antibody to HLA Activate Weibel-Palade Body Exocytosis. To test whether the effect of antibody to HLA requires clustering of HLA molecules, we compared several fragments of antibody to HLA, including the intact antibody (IgG), the bivalent F(abЈ) 2 , or the monovalent Fab (SI Fig. 12 ). The entire IgG antibody to HLA increases exocytosis (Fig. 5A) . Similarly, the bivalent F(abЈ) 2 triggers exocytosis. However, the monovalent Fab fragment has no effect on exocytosis.
We next added the monovalent Fab and then added goat antibody to mouse Fab to cross-link the monovalent Fab. Fab alone does not cause VWF release, but adding goat antibody to cross-link the Fab fragment increases exocytosis (Fig. 5B) . This finding suggests that antibody to HLA activates endothelial exocytosis by cross-linking HLA class I.
Antibody to HLA Activates Leukocyte Adherence to Endothelial Cells.
We next measured the functional consequences of antibody activation of endothelial exocytosis, using an ex vivo assay for leukocyte adherence. We added antibody to HLA to endothelial cells, next added fluorescently labeled HL-60 leukocytes, washed the cells, and measured the number of adherent leukocytes. Antibody to HLA increases leukocyte adherence to endothelial cells (Fig. 6 A  and B) . Pretreatment with the exocytosis inhibitor TAT-NSF222 also decreases antibody-induced exocytosis, showing that antibody to HLA increases endothelial exocytosis (Fig. 6 A and B) . Pretreatment with antibody to P-selectin decreases the effects of antibody upon exocytosis-dependent HL-60 binding, suggesting that leukocyte adherence is mediated in part by P-selectin (Fig. 6 A and B) . Furthermore, leukocyte adherence is not blocked by antibody to ICAM-1 or VCAM-1 (Fig. 6 C and D) . Taken together, these data show that antibody to HLA activates endothelial exocytosis and externalization of P-selectin, leading to leukocyte adherence.
Antibody to HLA Activates Endothelial Exocytosis in Vivo. We used a unique model of transplantation to explore the effects of antibody upon exocytosis in vivo. Severe combined immunodeficient (SCID)/ beige mice received two human skin grafts that retain superficial dermal human microvessels. Five weeks after transplantation, we injected mice with the F(abЈ) 2 portion of the antibody to HLA class I, or a control F(abЈ) 2 antibody. After 1 or 6 h, the mice were killed, and the skin graft was harvested, embedded, sectioned, and stained for VWF as a marker for exocytosis and myeloperoxidase (MPO) as a marker for neutrophil infiltration. After 1 h, the vessels in mice given the control antibody display the normal localization of VWF, as punctate staining of granules within endothelial cells (Fig. 7A Left) . Medium-sized vessels contain VWF containing granules in the endothelial intima (Fig. 7A Left, bottom right). Small vessels closer to the skin surface contain minimal staining for VWF in the intima (Fig. 7A Left, at the top) . In contrast, antibody to HLA after 1 h causes a shift in the location of VWF, from endothelial granules to the lumen and to the subendothelial space. Medium-sized vessels contain VWF in the lumen of the vessels (Fig. 7A Right, top right) . Furthermore, the lumen of numerous small vessels appears to be occluded with VWF ( Fig. 7A Right, lower left) . Finally, treatment with antibody to HLA also leads to VWF staining in the subendothelial space of vessels (Fig. 7A Right) . Evaluation and quantitation of VWF staining by observers blinded to the treatment groups confirms that antibody treatment increases VWF release within 1 h (Fig. 7B) . Thus antibody causes a shift in the pattern of VWF staining, from the intima into the lumen and also leads to an increase VWF in the lumen of small vessels. These changes are consistent with antibody triggering exocytosis.
Endothelial exocytosis externalizes P-selectin, which triggers leukocyte rolling along the endothelium. We therefore examined the effect of antibody to HLA upon leukocyte interactions with the vessel wall. We stained sections of human skin grafted onto SCID/beige mice for MPO, a marker of neutrophils. Few MPOpositive cells are present in skin grafts in mice treated with control antibody (Fig. 7 C and D; se also SI Fig. 13 ). However, antibody to human HLA after 1 h increases the adherence of MPO staining cells to dermal microvessels (Fig. 7 C and D; see also SI Fig. 13) .
We then examined mice 6 h after treatment with antibody to HLA. Antibody to HLA increases VWF staining in dermal microvessels (Fig. 7E) . Antibody to HLA also increases leukocyte infiltration into human skin grafts (Fig. 7 F and G) . Some leukocytes appear to have infiltrated into the tissue after 6 h. These data support a model in which antibody to HLA triggers the externalization of P-selectin, thus contributing to an increase in inflammation. Furthermore, some platelets appear in capillaries in mice treated with antibody to HLA but not with the control antibody (Fig. 7H) . These data suggest that antibody to HLA activates endothelial cell release of VWF, which is known to mediate intravascular platelet aggregation. Taken together, these data suggest that antibody to HLA activates endothelial exocytosis, releasing VWF and externalizing P-selectin, which lead to platelet aggregation and leukocyte infiltration.
Discussion
The major finding of this study is that antibody to HLA activates endothelial exocytosis in vitro and in vivo. These data suggest that one mechanism for antibody injury to transplanted organs is through antibody-triggering endothelial cell exocytosis, which in turn induces leukocyte trafficking.
How Does Antibody Activate Exocytosis? We found that two different antibodies to HLA class I can activate endothelial exocytosis, measured by VWF release, P-selectin externalization, and Pselectin-mediated leukocyte adherence (Figs. 1 and 6 ). Antibody activation of exocytosis depends upon cross-linking HLA class I, because an individual Fab fragment could not activate exocytosis (Fig. 5A) . Furthermore, cross-linking the monovalent Fab restored antibody induced exocytosis (Fig. 5B) .
How is cross-linking of HLA class I coupled to the exocytic machinery? Prior studies have shown that antibodies to HLA can trigger specific intracellular signal transduction cascades, including NF-B, tyrosine kinases, and generation of inositol phosphate (21) . IP3 in turn activates the IP3 receptor to release internal stores of calcium. We found that calcium is a critical mediator of antibody induced exocytosis (Fig. 4B) .
Antibody Activates Exocytosis by Complement-Independent Pathways. Previous studies have shown that C5a can stimulate endothelial cells through their C5a receptor to release of VWF and exteriorization of P-selectin (14). We speculated that C5a may add to the antibody induction of exocytosis, because specific classes of antibody can fix complement. However, C5a alone had only a minor effect upon endothelial exocytosis (Fig. 2) , and C5a in conjunction with antibody increased VWF release only slightly above levels induced by antibody alone (Fig. 3) . Although complement fixation by antibody is a component of acute rejection, our results suggest that antibody can activate exocytosis independent of complement (11) .
Antibody Induces Exocytosis in Vivo. The F(abЈ) 2 fragment of the antibody to HLA injected into mice caused release of VWF from endothelial cells in human skin grafts. VWF shifted location from endothelial cells into the lumen and into the subendothelial space of medium-sized vessels (Fig. 7) . Furthermore, small vessels in human skin grafts appeared plugged with VWF after antibody administration (Fig. 7) . Finally, antibody treatment increases neutrophil infiltration into human skin grafts (Fig. 7) . Endothelial degranulation can be observed at 1 h after antibody treatment, and the paucity of neutrophils at this time point suggests that antibody (rather than neutrophils) causes endothelial exocytosis. Although antibody also causes shifts in VWF and an even more striking increase in neutrophils after 6 h, other factors triggered by antibody may also contribute to endothelial degranulation and neutrophil adherence after 6 h, such as the synthesis of new proteins. However, these data suggest that antibody to human HLA could activate endothelial cells and inflammation in humans independently of the complement system. Implications for Diseases: Graft Rejection. Pathological changes in vascular endothelial cells are a prominent effect of antibodymediated rejection, including swelling of endothelial cells and adhesion of platelets and mononuclear cells (11, 22) . Our data imply that antibodies can cause vascular inflammation in transplanted organs by triggering endothelial cell exocytosis. If exocytosis plays a role in the pathogenesis of graft rejection, our identification of antibodies as exocytosis inducers suggests that exocytosis is a novel therapeutic target. The invention of new drugs that inhibit endothelial exocytosis may prove useful in treating antibody-induced inflammatory disorders.
Materials and Methods
Materials. The antibody to HLA W6/32 was purchased from SigmaAldrich (St. Louis, MO); the antibody to HLA-A,B,C #G46-2.6 was from BD Biosciences (San Diego, CA). Fragments of W6/32, including F(abЈ) 2 and Fab, were prepared by using a kit according to the manufacturer's instructions (ImmunoPure Fab Preparation Kit; Pierce, Rockford, IL). The antibody to cross-link the F(ab) fragment was goat anti-mouse IgG that was cleaved and purified to the F(abЈ) 2 fragment (Sigma). The control antibody injected into mice was ChromPure mouse IgG F(abЈ) 2 fragment (Jackson ImmunoResearch, West Grove, PA).
Cell Culture and Analysis of VWF Release from HAEC. HAEC and HMVEC and EGM-2 medium were obtained from Clonetics (Walkersville, MD). Cells were pretreated with known concentrations of reagents for 1 h in triplicate, washed, and stimulated with antibody W6/32 in fresh serum-free EGM-2 medium for 1 h for dose-dependency experiments or for 0-1 h for time-course experiments. The cell medium was collected, and the VWF concentration was quantified by using an ELISA from American Diagnostica (Stamford, CT).
Cell Toxicity Assays. We added formazan to HAEC for 3 h and then measured absorbance at 595 nm as an index of cell viability (Sigma-Aldrich). To measure apoptosis, HAEC were incubated with annexin V and propidium iodide and analyzed by FACS.
FACS Analysis for HLA and P-Selectin. Cells were incubated with a mouse monoclonal antibody G46-2.6, washed, and then incubated with an anti-mouse antibody conjugated to phycoerythrin (PE), washed, trypsinized, and analyzed by FACS. To analyze P-selectin localization on the surface of endothelial cells, the same procedure was repeated by using a PE-conjugated antibody to P-selectin.
Leukocyte Adhesion to HAEC in Vitro. HL-60 cells were loaded with 5 M BCEF-A M (2Ј,7Ј-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester), washed with Hanks' balanced salt solution (HBSS), and then added to HAEC. The cells were cocultured at 4°C for 15 min, washed with HBSS, and photographed with a fluorescence microscope at ϫ10 over an area 520 ϫ 700 m. Digital images were adjusted in Adobe Photoshop (Adobe Systems, San Jose, CA) only by adjusting levels in a linear function over the entire image.
Antibody Induction of Exocytosis in Vivo. SCID/beige mice were orthotopically transplanted with human skin grafts as described (23, 24) . Briefly, human skin was obtained from cadaveric donors through the Yale University Skin Bank under a protocol approved by the Yale Human Investigations Committee. Human skin in 0.5-mm-thick sheets was divided into 1-cm 2 pieces and fixed onto similarly sized defects on the dorsum of recipients using staples. The skin reproducibly grafted with a Ͼ95% success rate and was allowed to heal for 4-5 weeks. Mice were injected intravenously by tail vein injection with 7 g of F(abЈ) 2 fragment of W6/32 antibody or injected with 7 g of F(abЈ) 2 fragment of a control antibody. After 1 or 6 h, the mice were killed, and the skin was harvested and fixed in a modified Carnoy's solution, paraffin-embedded, and sectioned. Tissue sections were stained by a standard immunoperoxidase technique of avidin-biotinylated enzyme complex for the expression of VWF with a purified polyclonal rabbit antibody to VWF and, for the expression of MPO, with a purified polyclonal rabbit antibody to MPO.
Statistical Analysis. Experimental conditions were compared by using Student's t test for single measurements or ANOVA for repeated measurements. The null hypothesis was rejected where the P values were Ͻ0.05.
